Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
4
×
national blog main
boston blog main
boston top stories
fda
national top stories
alnylam pharmaceuticals
biotech
boston
deals
gene therapy
national
new york blog main
new york top stories
san diego blog main
san diego top stories
sarepta therapeutics
acute lymphoblastic leukemia
akcea therapeutics
ambys medicines
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
athenex
biomarin pharmaceutical
biopharma
bluebird bio
boulder/denver blog main
boulder/denver top stories
catalyst healthcare consultants
cell therapy
centers for medicare & medicaid services
chris collins
clinical trials
competitive generic therapy
cystic fibrosis
detroit blog main
detroit top stories
drug information association
drugs
What
fda
4
×
gene
4
×
therapy
drug
medicine
rna
alnylam
approval
approves
aren’t
betting
billion
bio
biopharma
cells
chemistry
cmc
consistent
controls
deal
developers
drugs
duchenne
ema
employ
ensure
europe
follows
harmful
help
historic
hits
imminent
interference
lack
long
make
manufacturing
medicare
method
Language
unset
Current search:
gene
×
fda
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
